A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation
NCT ID: NCT05776108
Last Updated: 2023-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2023-03-23
2023-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAB IR Formulation (reference)/CAB DT Formulation (Test 1)/CAB DT Formulation (Test 2)
Participants will receive CAB IR Formulation (reference) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment .
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
CAB DT Formulation (Test 1)/CAB IR Formulation (reference)/CAB DT Formulation (test 2)
Participants will receive CAB DT Formulation (test 1) under fasted conditions in treatment period 1 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
CAB DT Formulation (test 2)/CAB IR Formulation (reference)/CAB DT Formulation (test 1)
Participants will receive CAB DT Formulation (test 2) under fed conditions in treatment period 1 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
CAB IR Formulation (reference)/CAB DT Formulation (test 2)/CAB DT Formulation (test 1)
Participants will receive CAB IR Formulation (reference) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 2 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
CAB DT Formulation (test 1)/CAB DT Formulation (test 2)/CAB IR Formulation (reference)
Participants will receive CAB DT Formulation (test 1) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 2 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
CAB DT Formulation (test 2)/CAB DT Formulation (test 1)/CAB IR Formulation (reference)
Participants will receive CAB DT Formulation (test 2) under fed conditions in treatment period 1 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 2 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabotegravir IR Formulation (reference)
Cabotegravir IR Formulation (reference) will be administered.
Cabotegravir DT Formulation (test 1)
Cabotegravir DT Formulation (test 1) will be administered.
Cabotegravir DT Formulation (test 2)
Cabotegravir DT Formulation (test 2) will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and electrocardiogram).
* Body weight greater than or equal to (\>=) 50.0 kilograms (kg) (110 pounds \[lbs\]) for males and \>= 45 kg (99 lbs) for females and Body mass index within the range 18.5 to 31.0 kilogram per meter square (kg/m2) (inclusive) at Screening.
* Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Female: A female participant is eligible to participate if she is not pregnant or breastfeeding and is a Women of non child bearing potential (WONCBP) OR Is a Women of child bearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of less than (\<)1 percent (%) per year).
* A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention (i.e., Day-1 of each treatment Period)
* The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
* Capable of giving signed informed consent.
Exclusion Criteria
* History of seizures, and participants are required to have been seizure free, off anti epileptic drugs for a minimum of 2 years and will only be considered for enrollment following discussion with the Medical Monitor
* Abnormal blood pressure as determined by the investigator.
* Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3 months, or cardiac disease or a family or personal history of long QT syndrome.
* A pre-existing condition interfering with normal gastrointestinal anatomy or motility (e.g., gastroesophageal reflux disease, gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study intervention.
* Known suspected active Coronavirus disease 2019 (COVID-19) infection OR contact with an individual with known COVID-19 , within 14 days of study enrollment
* Any acute laboratory abnormality at screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
* Any Grade 2 to 4 laboratory abnormality at screening, with Creatine Phosphokinase and lipid abnormalities (e.g., total cholesterol, triglycerides), and ALT abnormalities, will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor.
* A positive test result for drugs of abuse (including marijuana), alcohol, or tobacco (indicating active current smoking) at screening or before the first dose of study intervention.
* Unable to refrain from the use of prescription or non-prescription drugs as detailed in the protocol.
* Unwillingness to abstain from excessive consumption of any food or drink detailed in the protocol.
* Would not be able to accommodate the blood loss during participation in the study
* Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
* Current enrollment or past participation in another investigational study as detailed in the protocol.
* Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing. - Current enrollment or past participation in this clinical study.
* Positive hepatitis B and/or C test result at screening or within 3 months prior to first dose of study intervention.
* Positive pre-study drug/alcohol screen, including Tetrahydrocannabinol
* Positive Human immunodeficiency virus (HIV) antibody test (4th generation assay required).
* Regular use of tobacco- or nicotine-containing products within 6 months prior to screening
* History of regular alcohol consumption within 6 months of the study,
* History of sensitivity, prior intolerance or hypersensitivity to any of the study interventions, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
* Participant and/or his her family is part of sponsor, clinical site, third party personnel.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ViiV Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
ViiV Healthcare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
219679
Identifier Type: -
Identifier Source: org_study_id